$ORGO Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Organogenesis Holdings Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Organogenesis Holdings Inc.. Get notifications about new insider transactions in Organogenesis Holdings Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 28 2021 | ORGO | Organogenesis Hold ... | Erani Dennis | 10% Owner | Sell | S | 18.97 | 9,106 | 172,741 | 1,314,517 | 1.3 M to 1.3 M (-0.69 %) |
Jun 10 2021 | ORGO | Organogenesis Hold ... | ERANI ALBERT | 10% Owner | Sell | S | 15.31 | 150,000 | 2,296,500 | 59,432,133 | 59.6 M to 59.4 M (-0.25 %) |
Jun 10 2021 | ORGO | Organogenesis Hold ... | Albert Erani Family Trust date ... | 10% Owner | Sell | S | 15.31 | 150,000 | 2,296,500 | 59,432,133 | 59.6 M to 59.4 M (-0.25 %) |
May 28 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Sell | S | 16.40 | 3,887,500 | 63,755,000 | 59,836,745 | 63.7 M to 59.8 M (-6.10 %) |
May 11 2021 | ORGO | Organogenesis Hold ... | Giacomin Jon L | Director | Grant | A | 0.00 | 5,319 | 0 | 5,319 | 0 to 5.3 K |
May 10 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | J | 0.00 | 5,417,900 | 0 | 63,724,507 | 58.3 M to 63.7 M (+9.29 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | J | 0.00 | 4,661,129 | 0 | 58,306,607 | 53.6 M to 58.3 M (+8.69 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | J | 0.00 | 5,417,900 | 0 | 63,724,507 | 58.3 M to 63.7 M (+9.29 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | J | 0.00 | 115,685 | 0 | 53,645,478 | 53.5 M to 53.6 M (+0.22 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | J | 0.00 | 4,661,129 | 0 | 58,306,607 | 53.6 M to 58.3 M (+8.69 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | J | 0.00 | 9,235,495 | 0 | 53,529,793 | 44.3 M to 53.5 M (+20.85 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | J | 0.00 | 115,685 | 0 | 53,645,478 | 53.5 M to 53.6 M (+0.22 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | J | 0.00 | 120,505 | 0 | 44,294,298 | 44.2 M to 44.3 M (+0.27 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | J | 0.00 | 9,235,495 | 0 | 53,529,793 | 44.3 M to 53.5 M (+20.85 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Sell | J | 0.00 | 23,855,148 | 0 | 44,173,793 | 68 M to 44.2 M (-35.07 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | J | 0.00 | 120,505 | 0 | 44,294,298 | 44.2 M to 44.3 M (+0.27 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Sell | J | 0.00 | 23,855,148 | 0 | 44,173,793 | 68 M to 44.2 M (-35.07 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | J | 0.00 | 5,417,900 | 0 | 63,724,507 | 58.3 M to 63.7 M (+9.29 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | J | 0.00 | 4,661,129 | 0 | 58,306,607 | 53.6 M to 58.3 M (+8.69 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | J | 0.00 | 5,417,900 | 0 | 63,724,507 | 58.3 M to 63.7 M (+9.29 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | J | 0.00 | 115,685 | 0 | 53,645,478 | 53.5 M to 53.6 M (+0.22 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | J | 0.00 | 4,661,129 | 0 | 58,306,607 | 53.6 M to 58.3 M (+8.69 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | J | 0.00 | 9,235,495 | 0 | 53,529,793 | 44.3 M to 53.5 M (+20.85 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | J | 0.00 | 115,685 | 0 | 53,645,478 | 53.5 M to 53.6 M (+0.22 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | J | 0.00 | 120,505 | 0 | 44,294,298 | 44.2 M to 44.3 M (+0.27 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | J | 0.00 | 9,235,495 | 0 | 53,529,793 | 44.3 M to 53.5 M (+20.85 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Sell | J | 0.00 | 23,855,148 | 0 | 44,173,793 | 68 M to 44.2 M (-35.07 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | J | 0.00 | 120,505 | 0 | 44,294,298 | 44.2 M to 44.3 M (+0.27 %) |
May 10 2021 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Sell | J | 0.00 | 23,855,148 | 0 | 44,173,793 | 68 M to 44.2 M (-35.07 %) |
Apr 05 2021 | ORGO | Organogenesis Hold ... | Grow Brian | Chief Commercial Of ... | Payment of Exercise | F | 19.83 | 1,977 | 39,204 | 44,572 | 46.5 K to 44.6 K (-4.25 %) |
Apr 05 2021 | ORGO | Organogenesis Hold ... | Bilbo Patrick | Chief Operating Off ... | Payment of Exercise | F | 19.83 | 2,497 | 49,516 | 164,120 | 166.6 K to 164.1 K (-1.50 %) |
Apr 05 2021 | ORGO | Organogenesis Hold ... | Freedman Lori | VP and General Coun ... | Payment of Exercise | F | 19.83 | 1,975 | 39,164 | 33,751 | 35.7 K to 33.8 K (-5.53 %) |
Apr 05 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Payment of Exercise | F | 19.83 | 6,265 | 124,235 | 133,542 | 139.8 K to 133.5 K (-4.48 %) |
Apr 05 2021 | ORGO | Organogenesis Hold ... | Montecalvo Antonio S. | VP Health Policy & ... | Payment of Exercise | F | 19.83 | 1,770 | 35,099 | 69,556 | 71.3 K to 69.6 K (-2.48 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Francisco David | Chief Financial Off ... | Option Exercise | A | 13.68 | 83,955 | 1,148,504 | 83,955 | |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Francisco David | Chief Financial Off ... | Grant | A | 0.00 | 10,965 | 0 | 16,361 | 5.4 K to 16.4 K (+203.21 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Montecalvo Antonio S. | VP Health Policy & ... | Option Exercise | A | 13.68 | 63,246 | 865,205 | 63,246 | |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Montecalvo Antonio S. | VP Health Policy & ... | Grant | A | 0.00 | 8,260 | 0 | 71,326 | 63.1 K to 71.3 K (+13.10 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Grow Brian | Chief Commercial Of ... | Option Exercise | A | 13.68 | 82,556 | 1,129,366 | 82,556 | |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Grow Brian | Chief Commercial Of ... | Grant | A | 0.00 | 10,782 | 0 | 46,549 | 35.8 K to 46.5 K (+30.15 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Freedman Lori | VP and General Coun ... | Option Exercise | A | 13.68 | 67,444 | 922,634 | 67,444 | |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Freedman Lori | VP and General Coun ... | Grant | A | 0.00 | 8,808 | 0 | 35,726 | 26.9 K to 35.7 K (+32.72 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Bilbo Patrick | Chief Operating Off ... | Option Exercise | A | 13.68 | 82,556 | 1,129,366 | 82,556 | |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Bilbo Patrick | Chief Operating Off ... | Grant | A | 0.00 | 10,782 | 0 | 166,617 | 155.8 K to 166.6 K (+6.92 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Option Exercise | A | 13.68 | 395,289 | 5,407,554 | 395,289 | |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Sell | S | 12.85 | 16,663 | 214,120 | 139,807 | 156.5 K to 139.8 K (-10.65 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Sell | S | 13.82 | 11,174 | 154,425 | 156,470 | 167.6 K to 156.5 K (-6.67 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Sell | S | 13.30 | 78,201 | 1,040,073 | 167,644 | 245.8 K to 167.6 K (-31.81 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Grant | A | 0.00 | 51,626 | 0 | 245,845 | 194.2 K to 245.8 K (+26.58 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | MACKIE WAYNE D | Director | Grant | A | 0.00 | 5,482 | 0 | 211,800 | 206.3 K to 211.8 K (+2.66 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | MACKIE WAYNE D | Director | Grant | A | 0.00 | 6,318 | 0 | 206,318 | 200 K to 206.3 K (+3.16 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Tamaroff Joshua Alexander | Director | Grant | A | 0.00 | 5,482 | 0 | 30,364 | 24.9 K to 30.4 K (+22.03 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Tamaroff Joshua Alexander | Director | Grant | A | 0.00 | 6,318 | 0 | 24,882 | 18.6 K to 24.9 K (+34.03 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Leibowitz Arthur S | Director | Grant | A | 0.00 | 5,482 | 0 | 42,307 | 36.8 K to 42.3 K (+14.89 %) |
Feb 18 2021 | ORGO | Organogenesis Hold ... | Leibowitz Arthur S | Director | Grant | A | 0.00 | 6,318 | 0 | 36,825 | 30.5 K to 36.8 K (+20.71 %) |
Feb 17 2021 | ORGO | Organogenesis Hold ... | Francisco David | Chief Financial Off ... | Option Exercise | A | 12.74 | 43,239 | 550,865 | 43,239 | |
Feb 17 2021 | ORGO | Organogenesis Hold ... | Francisco David | Chief Financial Off ... | Grant | A | 0.00 | 5,396 | 0 | 5,396 | 0 to 5.4 K |
Feb 16 2021 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Sell | S | 3.25 | 200,000 | 650,000 | 68,594,976 | 68.8 M to 68.6 M (-0.29 %) |
Feb 16 2021 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Sell | S | 3.25 | 200,000 | 650,000 | 68,594,976 | 68.8 M to 68.6 M (-0.29 %) |
Feb 16 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Sell | S | 13.12 | 111,406 | 1,461,647 | 194,219 | 305.6 K to 194.2 K (-36.45 %) |
Feb 16 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Sell | S | 13.77 | 33,391 | 459,794 | 305,625 | 339 K to 305.6 K (-9.85 %) |
Feb 16 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Sell | S | 12.96 | 77,938 | 1,010,076 | 339,016 | 417 K to 339 K (-18.69 %) |
Feb 16 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Sell | S | 13.82 | 69,127 | 955,335 | 416,954 | 486.1 K to 417 K (-14.22 %) |
Feb 16 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Sell | S | 13.12 | 111,406 | 1,461,647 | 194,219 | 305.6 K to 194.2 K (-36.45 %) |
Feb 16 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Sell | S | 13.77 | 33,391 | 459,794 | 305,625 | 339 K to 305.6 K (-9.85 %) |
Feb 16 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Sell | S | 12.96 | 77,938 | 1,010,076 | 339,016 | 417 K to 339 K (-18.69 %) |
Feb 16 2021 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Sell | S | 13.82 | 69,127 | 955,335 | 416,954 | 486.1 K to 417 K (-14.22 %) |
Jan 15 2021 | ORGO | Organogenesis Hold ... | Hagopian Henry III | Interim CFO | Option Exercise | A | 7.34 | 64,198 | 471,213 | 64,198 | |
Jan 15 2021 | ORGO | Organogenesis Hold ... | Hagopian Henry III | Interim CFO | Grant | A | 0.00 | 10,700 | 0 | 12,073 | 1.4 K to 12.1 K (+779.32 %) |
Nov 19 2020 | ORGO | Organogenesis Hold ... | KATZ MICHAEL W | 10% Owner | Buy | P | 3.25 | 20,829 | 67,694 | 34,432 | 13.6 K to 34.4 K (+153.12 %) |
Nov 19 2020 | ORGO | Organogenesis Hold ... | MACKIE WAYNE D | Director | Buy | P | 3.25 | 42,726 | 138,860 | 161,290 | 118.6 K to 161.3 K (+36.04 %) |
Nov 19 2020 | ORGO | Organogenesis Hold ... | Leibowitz Arthur S | Director | Buy | P | 3.25 | 6,943 | 22,565 | 30,507 | 23.6 K to 30.5 K (+29.46 %) |
Nov 19 2020 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | P | 3.25 | 347,153 | 1,128,247 | 68,794,976 | 68.4 M to 68.8 M (+0.51 %) |
Nov 19 2020 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | P | 3.25 | 486,000 | 1,579,500 | 68,447,823 | 68 M to 68.4 M (+0.72 %) |
Nov 19 2020 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | P | 3.25 | 347,153 | 1,128,247 | 68,794,976 | 68.4 M to 68.8 M (+0.51 %) |
Nov 19 2020 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | P | 3.25 | 347,153 | 1,128,247 | 68,794,976 | 68.4 M to 68.8 M (+0.51 %) |
Nov 19 2020 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | P | 3.25 | 486,000 | 1,579,500 | 68,447,823 | 68 M to 68.4 M (+0.72 %) |
Nov 19 2020 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | P | 3.25 | 486,000 | 1,579,500 | 68,447,823 | 68 M to 68.4 M (+0.72 %) |
Aug 25 2020 | ORGO | Organogenesis Hold ... | Hagopian Henry III | Interim CFO | Option Exercise | A | 4.46 | 15,000 | 66,900 | 15,000 | |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Tamaroff Joshua Alexander | Director | Grant | A | 0.00 | 18,564 | 0 | 18,564 | 0 to 18.6 K |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Tamaroff Joshua Alexander | Director | Grant | A | 0.00 | 18,564 | 0 | 18,564 | 0 to 18.6 K |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Leibowitz Arthur S | Director | Grant | A | 0.00 | 18,564 | 0 | 23,564 | 5 K to 23.6 K (+371.28 %) |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Leibowitz Arthur S | Director | Grant | A | 0.00 | 18,564 | 0 | 23,564 | 5 K to 23.6 K (+371.28 %) |
Apr 24 2020 | ORGO | Organogenesis Hold ... | MACKIE WAYNE D | Director | Grant | A | 0.00 | 18,564 | 0 | 118,564 | 100 K to 118.6 K (+18.56 %) |
Apr 24 2020 | ORGO | Organogenesis Hold ... | MACKIE WAYNE D | Director | Grant | A | 0.00 | 18,564 | 0 | 118,564 | 100 K to 118.6 K (+18.56 %) |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Freedman Lori | VP and General Coun ... | Option Exercise | A | 4.04 | 177,310 | 716,332 | 177,310 | |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Freedman Lori | VP and General Coun ... | Grant | A | 0.00 | 26,918 | 0 | 26,918 | 0 to 26.9 K |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Bilbo Patrick | Chief Operating Off ... | Option Exercise | A | 4.04 | 224,185 | 905,707 | 224,185 | |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Bilbo Patrick | Chief Operating Off ... | Grant | A | 0.00 | 34,035 | 0 | 155,835 | 121.8 K to 155.8 K (+27.94 %) |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Grow Brian | Chief Commercial Of ... | Option Exercise | A | 4.04 | 213,995 | 864,540 | 213,995 | |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Grow Brian | Chief Commercial Of ... | Grant | A | 0.00 | 32,488 | 0 | 35,767 | 3.3 K to 35.8 K (+990.79 %) |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Cunningham Timothy M. | Chief Financial Off ... | Option Exercise | A | 4.04 | 183,424 | 741,033 | 183,424 | |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Cunningham Timothy M. | Chief Financial Off ... | Grant | A | 0.00 | 27,847 | 0 | 27,847 | 0 to 27.8 K |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Option Exercise | A | 4.04 | 580,842 | 2,346,602 | 580,842 | |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Grant | A | 0.00 | 88,181 | 0 | 486,081 | 397.9 K to 486.1 K (+22.16 %) |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Montecalvo Antonio S. | VP Health Policy & ... | Option Exercise | A | 4.04 | 158,967 | 642,227 | 158,967 | |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Montecalvo Antonio S. | VP Health Policy & ... | Option Exercise | M | 1.70 | 30,450 | 51,765 | 0 | |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Montecalvo Antonio S. | VP Health Policy & ... | Grant | A | 0.00 | 24,134 | 0 | 63,066 | 38.9 K to 63.1 K (+61.99 %) |
Apr 24 2020 | ORGO | Organogenesis Hold ... | Montecalvo Antonio S. | VP Health Policy & ... | Buy | M | 1.70 | 30,450 | 51,765 | 38,932 | 8.5 K to 38.9 K (+359.00 %) |
Apr 16 2020 | ORGO | Organogenesis Hold ... | Grow Brian | Chief Commercial Of ... | Option Exercise | M | 1.70 | 1,150 | 1,955 | 1 | |
Apr 16 2020 | ORGO | Organogenesis Hold ... | Grow Brian | Chief Commercial Of ... | Option Exercise | M | 1.70 | 667 | 1,134 | 0 | |
Apr 16 2020 | ORGO | Organogenesis Hold ... | Grow Brian | Chief Commercial Of ... | Buy | M | 1.70 | 1,150 | 1,955 | 3,279 | 2.1 K to 3.3 K (+54.02 %) |
Apr 16 2020 | ORGO | Organogenesis Hold ... | Grow Brian | Chief Commercial Of ... | Buy | M | 1.70 | 667 | 1,134 | 2,129 | 1.5 K to 2.1 K (+45.62 %) |
Mar 16 2020 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Buy | P | 3.98 | 75,000 | 298,133 | 25,517,514 | 25.4 M to 25.5 M (+0.29 %) | |
Mar 16 2020 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Buy | P | 4.31 | 135,000 | 581,283 | 25,442,514 | 25.3 M to 25.4 M (+0.53 %) | |
Mar 16 2020 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Buy | P | 4.17 | 141,462 | 590,378 | 25,307,514 | 25.2 M to 25.3 M (+0.56 %) | |
Mar 16 2020 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Buy | P | 3.62 | 190,887 | 691,164 | 25,166,052 | 25 M to 25.2 M (+0.76 %) | |
Feb 07 2020 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Option Exercise | M | 1.70 | 397,900 | 676,430 | 0 | |
Feb 07 2020 | ORGO | Organogenesis Hold ... | Gillheeney Gary S. | President and CEO | Buy | M | 1.70 | 397,900 | 676,430 | 397,900 | 0 to 397.9 K |
Nov 27 2019 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Buy | P | 5.00 | 6,000,000 | 30,000,000 | 24,975,165 | 19 M to 25 M (+31.62 %) | |
Sep 16 2019 | ORGO | Organogenesis Hold ... | KATZ MICHAEL W | 10% Owner | Buy | P | 6.00 | 3,603 | 21,618 | 13,603 | 10 K to 13.6 K (+36.03 %) |
Sep 16 2019 | ORGO | Organogenesis Hold ... | MACKIE WAYNE D | Director | Buy | P | 6.07 | 1,032 | 6,268 | 100,000 | 99 K to 100 K (+1.04 %) |
Sep 16 2019 | ORGO | Organogenesis Hold ... | MACKIE WAYNE D | Director | Buy | P | 6.14 | 3,958 | 24,302 | 98,968 | 95 K to 99 K (+4.17 %) |
Sep 13 2019 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Buy | P | 6.25 | 413,900 | 2,585,344 | 18,975,165 | 18.6 M to 19 M (+2.23 %) | |
Sep 13 2019 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Buy | P | 5.75 | 447,000 | 2,570,429 | 18,561,265 | 18.1 M to 18.6 M (+2.47 %) | |
Sep 11 2019 | ORGO | Organogenesis Hold ... | MACKIE WAYNE D | Director | Buy | P | 5.80 | 3,133 | 18,171 | 95,010 | 91.9 K to 95 K (+3.41 %) |
Sep 11 2019 | ORGO | Organogenesis Hold ... | MACKIE WAYNE D | Director | Buy | P | 5.17 | 8,877 | 45,896 | 91,877 | 83 K to 91.9 K (+10.70 %) |
Sep 11 2019 | ORGO | Organogenesis Hold ... | MACKIE WAYNE D | Director | Buy | P | 4.95 | 1,000 | 4,950 | 83,000 | 82 K to 83 K (+1.22 %) |
Sep 10 2019 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | P | 5.03 | 10,000 | 50,274 | 67,961,823 | 68 M to 68 M (+0.01 %) |
Sep 10 2019 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | P | 5.03 | 10,000 | 50,274 | 67,961,823 | 68 M to 68 M (+0.01 %) |
Sep 10 2019 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | P | 5.03 | 10,000 | 50,274 | 67,961,823 | 68 M to 68 M (+0.01 %) |
Sep 10 2019 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | P | 5.03 | 10,000 | 50,274 | 67,961,823 | 68 M to 68 M (+0.01 %) |
Sep 10 2019 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Buy | P | 5.18 | 12,000 | 62,207 | 18,114,265 | 18.1 M to 18.1 M (+0.07 %) | |
Sep 10 2019 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Buy | P | 5.12 | 25,000 | 128,023 | 18,102,265 | 18.1 M to 18.1 M (+0.14 %) | |
Sep 10 2019 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Buy | P | 5.18 | 500,000 | 2,592,300 | 18,077,265 | 17.6 M to 18.1 M (+2.84 %) | |
Sep 05 2019 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Buy | P | 4.89 | 177,600 | 868,571 | 17,577,265 | 17.4 M to 17.6 M (+1.02 %) | |
Sep 05 2019 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Buy | P | 4.90 | 200,000 | 979,220 | 17,399,665 | 17.2 M to 17.4 M (+1.16 %) | |
Sep 05 2019 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Buy | P | 4.75 | 200,000 | 949,760 | 17,199,665 | 17 M to 17.2 M (+1.18 %) | |
Sep 05 2019 | ORGO | Organogenesis Hold ... | Leibowitz Arthur S | Director | Buy | P | 4.20 | 5,000 | 21,000 | 5,000 | 0 to 5 K |
Sep 05 2019 | ORGO | Organogenesis Hold ... | MACKIE WAYNE D | Director | Buy | P | 4.70 | 32,000 | 150,506 | 82,000 | 50 K to 82 K (+64.00 %) |
Sep 05 2019 | ORGO | Organogenesis Hold ... | MACKIE WAYNE D | Director | Buy | P | 4.31 | 50,000 | 215,705 | 50,000 | 0 to 50 K |
Sep 05 2019 | ORGO | Organogenesis Hold ... | KATZ MICHAEL W | 10% Owner | Buy | P | 4.50 | 10,000 | 44,975 | 10,000 | 0 to 10 K |
Sep 05 2019 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | P | 4.53 | 5,000 | 22,664 | 67,951,823 | 67.9 M to 68 M (+0.01 %) |
Sep 05 2019 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | P | 4.62 | 50,000 | 231,190 | 67,946,823 | 67.9 M to 67.9 M (+0.07 %) |
Sep 05 2019 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | P | 4.25 | 100 | 425 | 67,896,823 | 67.9 M to 67.9 M (0.00 %) |
Sep 05 2019 | ORGO | Organogenesis Hold ... | NUSSDORF GLENN H | Director | Buy | P | 4.38 | 50,000 | 218,930 | 67,896,723 | 67.8 M to 67.9 M (+0.07 %) |
Sep 05 2019 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | P | 4.53 | 5,000 | 22,664 | 67,951,823 | 67.9 M to 68 M (+0.01 %) |
Sep 05 2019 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | P | 4.62 | 50,000 | 231,190 | 67,946,823 | 67.9 M to 67.9 M (+0.07 %) |
Sep 05 2019 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | P | 4.25 | 100 | 425 | 67,896,823 | 67.9 M to 67.9 M (0.00 %) |
Sep 05 2019 | ORGO | Organogenesis Hold ... | Ades Alan A. | Director | Buy | P | 4.38 | 50,000 | 218,930 | 67,896,723 | 67.8 M to 67.9 M (+0.07 %) |
Aug 21 2019 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Option Exercise | D | 0.00 | 4,100,000 | 0 | 0 | ||
Aug 21 2019 | ORGO | Organogenesis Hold ... | Avista Capital Managing Member ... | Grant | A | 0.00 | 389,501 | 0 | 16,999,665 | 16.6 M to 17 M (+2.34 %) | |
May 24 2019 | ORGO | Organogenesis Hold ... | KATZ MICHAEL W | 10% Owner | Option Exercise | A | 7.08 | 100,000 | 708,000 | 100,000 | |
Dec 12 2018 | AHPA | Organogenesis Hold ... | Freedman Lori | VP and General Coun ... | Option Exercise | A | 5.40 | 40,600 | 219,240 | 40,600 | |
Dec 12 2018 | AHPA | Organogenesis Hold ... | Cunningham Timothy M. | Chief Financial Off ... | Option Exercise | A | 3.46 | 559,620 | 1,936,285 | 559,620 | |
Dec 12 2018 | AHPA | Organogenesis Hold ... | Bilbo Patrick | Chief Operating Off ... | Option Exercise | A | 3.46 | 101,500 | 351,190 | 101,500 | |
Dec 12 2018 | AHPA | Organogenesis Hold ... | Bilbo Patrick | Chief Operating Off ... | Option Exercise | A | 3.46 | 142,100 | 491,666 | 142,100 | |
Dec 12 2018 | AHPA | Organogenesis Hold ... | Bilbo Patrick | Chief Operating Off ... | Option Exercise | A | 1.18 | 152,250 | 179,655 | 152,250 | |
Dec 12 2018 | AHPA | Organogenesis Hold ... | Bilbo Patrick | Chief Operating Off ... | Option Exercise | A | 1.44 | 30,450 | 43,848 | 30,450 | |
Dec 12 2018 | AHPA | Organogenesis Hold ... | Bilbo Patrick | Chief Operating Off ... | Grant | A | 0.00 | 121,800 | 0 | 121,800 | 0 to 121.8 K |